Gilead Sciences Management
Management criteria checks 3/4
Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 5.08 years. total yearly compensation is $22.61M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth €30.32M. The average tenure of the management team and the board of directors is 4.2 years and 6.3 years respectively.
Key information
Dan O'Day
Chief executive officer
US$22.6m
Total compensation
CEO salary percentage | 7.7% |
CEO tenure | 5.1yrs |
CEO ownership | 0.04% |
Management average tenure | 4.2yrs |
Board average tenure | 6.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$23m | US$2m | US$6b |
Sep 30 2023 | n/a | n/a | US$6b |
Jun 30 2023 | n/a | n/a | US$5b |
Mar 31 2023 | n/a | n/a | US$6b |
Dec 31 2022 | US$22m | US$2m | US$5b |
Sep 30 2022 | n/a | n/a | US$3b |
Jun 30 2022 | n/a | n/a | US$4b |
Mar 31 2022 | n/a | n/a | US$5b |
Dec 31 2021 | US$19m | US$2m | US$6b |
Sep 30 2021 | n/a | n/a | US$7b |
Jun 30 2021 | n/a | n/a | US$5b |
Mar 31 2021 | n/a | n/a | US$301m |
Dec 31 2020 | US$19m | US$2m | US$123m |
Sep 30 2020 | n/a | n/a | US$1b |
Jun 30 2020 | n/a | n/a | -US$257m |
Mar 31 2020 | n/a | n/a | US$5b |
Dec 31 2019 | US$29m | US$1m | US$5b |
Compensation vs Market: Dan's total compensation ($USD22.61M) is above average for companies of similar size in the Italian market ($USD3.92M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan O'Day (59 yo)
5.1yrs
Tenure
US$22,607,690
Compensation
Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 5.1yrs | US$22.61m | 0.039% $ 30.3m | |
Chief Financial Officer | 4.4yrs | US$8.11m | 0.011% $ 8.4m | |
Executive VP of Corporate Affairs | 1.7yrs | US$5.27m | 0.0011% $ 857.7k | |
Chief Commercial Officer | 4.8yrs | US$8.59m | 0.0095% $ 7.4m | |
Chief Medical Officer | 4.4yrs | US$8.39m | 0.0077% $ 6.0m | |
Senior VP | 1.1yrs | no data | 0.0026% $ 2.0m | |
Vice President of Investor Relations | 3.3yrs | no data | no data | |
Executive Vice President of Human Resources | 4.7yrs | no data | no data | |
Senior Vice President of Research | 4.2yrs | no data | no data | |
Senior Vice President of Commercial Operations of Australia | no data | no data | no data | |
Executive Vice President of Research | 3yrs | no data | no data | |
Senior Vice President & Therapeutic Area Head of Gilead Oncology | 2.8yrs | no data | no data |
4.2yrs
Average Tenure
57yo
Average Age
Experienced Management: 1GILD's management team is considered experienced (4.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 5.1yrs | US$22.61m | 0.039% $ 30.3m | |
Independent Director | 3.5yrs | US$444.92k | 0.00064% $ 499.0k | |
Member of Scientific Advisory Board | no data | US$16.00k | no data | |
Independent Director | 6.3yrs | US$429.92k | 0.0018% $ 1.4m | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Lead Independent Director | 14.8yrs | US$507.44k | 0.0074% $ 5.8m | |
Independent Director | 7.7yrs | US$434.92k | 0.00011% $ 85.8k | |
Chairperson of Scientific Advisory Board | no data | no data | no data |
6.3yrs
Average Tenure
68yo
Average Age
Experienced Board: 1GILD's board of directors are considered experienced (6.3 years average tenure).